Quick answer

Tirzepatide’s diabetes label (2022): the SURPASS-program drug that beat semaglutide 1 mg on both A1c and weight in SURPASS-2 — billed through the diabetes benefit, with the weight-label sibling story living at Zepbound.

MoleculeTirzepatideLabelType 2 diabetes · approved 2022Dose ladder2.5 → 15 mg weeklyKey trialsSURPASS program · SURPASS-2: superior A1c and weight vs semaglutide 1 mgCoverage laneDiabetes benefit; step therapy through metformin commonOff-label historyThe shortage-era weight workaround — mostly obsolete since Zepbound

Deeper data: the trial index holds every figure above with sources; same drug, two labels, the molecule matchup.

Mounjaro is tirzepatide labeled for type 2 diabetes — the original 2022 approval that put the dual agonist on the map before Zepbound existed.

Indication and evidence

Approved to improve glycemic control in adults with type 2 diabetes alongside diet and exercise. The SURPASS program showed A1c reductions around two percentage points and, in SURPASS-2, superiority over semaglutide 1 mg on both glucose and weight. Substantial weight loss shows up in every SURPASS trial even though weight is not the label’s target.

Dosing

Identical ladder to Zepbound: 2.5 mg weekly to start, escalating in 2.5 mg steps to a 15 mg maximum, no faster than every four weeks.

Mounjaro vs Zepbound in practice

Same molecule, same strengths, different indication on the box. The distinction drives insurance behavior: diabetes coverage for Mounjaro is far more common than obesity coverage for Zepbound, which is why prior-authorization criteria — not pharmacology — decide many patients’ out-of-pocket reality (coverage file). Prescribing Mounjaro off-label for weight in people without diabetes happens, but payers increasingly audit for it.

Safety essentials

See the molecule page: boxed thyroid warning, GI titration burden, the oral-contraceptive interaction, and — relevant in diabetes — additive hypoglycemia risk when combined with insulin or sulfonylureas, which usually requires reducing those agents.

Costs and coverage in practice

Because the indication is diabetes, Mounjaro enjoys the broadest insurance coverage of any tirzepatide product — many commercial and Medicare Part D plans cover it with prior authorization tied to A1c and prior therapies, and the commercial savings card can pull copays down further. List price runs near four figures monthly (verify current). The perverse arithmetic this creates is worth stating plainly: the same molecule can cost a covered diabetes patient a modest copay and an uncovered weight-management patient a four-figure list price — which is precisely the gap the entire cash market on this site exists to fill.

Common confusions

“Mounjaro for weight loss” is off-label use of an on-label molecule — legal to prescribe, increasingly audited by payers, and pointless to pursue when Zepbound exists unless a formulary quirk makes Mounjaro the covered one. And Mounjaro is not “stronger” than Zepbound at equal dose — identical drug, identical strengths, different box.

Practical dosing notes

A missed weekly dose can be taken within 4 days (96 hours) per the tirzepatide label; beyond that, skip and resume schedule — never double. In diabetes care the drug is judged against an A1c goal, so escalation decisions weigh glucose control, weight, and tolerability together rather than chasing maximum dose by default.

References

Mounjaro prescribing information — pi.lilly.com. SURPASS-2, NEJM 2021. Related: head-to-head file.